Catheter device Acostream for serious blood clots in the lungs
Tests Acostream, a catheter suction device, in adults with serious pulmonary embolism.
Key facts
- Who runs it
- RenJi Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Acostream Use in Patients With High Risk and Intermediate-risk Acute Pulmonary Embolism
- Status
- Recruiting
- People taking part
- 127 people, planned
- Started
- 1 Apr 2025
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional
- Treatments tested
- Acostream aspiration
- Record updated
- 27 April 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with high-risk or intermediate-high-risk sudden blood clots in the lungs (pulmonary embolism). It tests clot removal through a thin tube using the Acostream device.
- Age
- 18 to 85 years
- Sex
- All sexes
- Disease stage
- Acute pulmonary embolism with symptoms for 14 days or less. High-risk patients, or intermediate-high-risk patients with a strained right side of the heart (right ventricle/left ventricle >0.9) seen on a CT scan of the lung vessels or a heart ultrasound.
- Earlier treatment
- High-risk patients must be unable to have clot-dissolving drugs given through a vein, or these drugs did not work (ongoing circulatory collapse). They also must not be able to have surgery to remove the clot.
- Biomarker or test result
- For intermediate-high-risk patients: right ventricle/left ventricle >0.9 on computed tomography pulmonary angiography or transthoracic echocardiography.
Main reasons for not taking part
- Pregnancy
- A blood clot inside the heart
- Long-term left heart failure with ejection fraction lower than 30%, or a diagnosed tendency to form blood clots (thrombophilia)
- History of severe or long-term high blood pressure in the lungs
- Serum creatinine higher than 1.8 mg/dl (159 µmol/L), or known serious uncontrolled sensitivity to X-ray contrast agents
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- 18≤Age≤85
- Clinical symptoms and presentation consistent with pulmonary embolism (PE)
- PE symptoms duration ≤ 14 days
- High risk PE patients with absolute contraindications to systemic thrombolysis or its failure (refractory circulatory collapse) not eligible for surgical embolectomy
- Intermediate-high risk PE patients with right ventricle dysfunction (right ventricle/ left ventricle >0.9) confirmed by computed tomography pulmonary angiography or transthoracic echocardiography
Who cannot take part
- History of severe or chronic pulmonary hypertension
- Presence of chronic left heart failure with an ejection fraction lower than 30% Diagnosed thrombophilia
- Serum creatinine level higher than 1.8 mg/dl
- Pregnancy
- Refusal to sign the informed consent form
- Presence of intracardiac thrombus
- Known serious and uncontrolled sensitivity to radiographic agents
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The registry is to evaluate the safety and feasibility of catheter-directed aspiration for patients with high-risk and intermediate-high-risk pulmonary embolism using Acostream.
The group in the trial
- The Acostream aspiration groupTreatment being tested
The pulmonary thrombus removal by Acostream.
Treatment: Acostream aspiration
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Acostream Use in Patients With High Risk and Intermediate-risk Acute Pulmonary Embolism (The ARTIST Study)
- Plain-language title
- Catheter device Acostream for serious blood clots in the lungsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT06946732, who can take part
- Record updated
- 27 April 2025